For 20 years, KIGS (Pfizer International Growth Database) has provided an outstanding tool for monitoring the use, efficacy and safety of growth hormone (GH) treatment in children with short stature of varying origin.
This volume offers a comprehensive update of the continuing experiences in KIGS and is based on data from more than 50 countries and more than 60,000 patients. International experts analyse in detail the basic auxological characteristics of patients and their response to GH treatment for a broad spectrum of growth disorders. These include idiopathic GH deficiency, organic GH deficiency due to a variety of causes such as congenital malformations and syndromes, genetic disorders or treatment for leukaemia or central nervous system tumours and short stature in children born small for gestational age, specific syndromes and systemic disorders. Each growth disorder is also covered by a review of relevant published data by international experts.
KIGS has also established itself as a primary source of information about adverse events during long-term GH treatment in children. The recent analysis of KIGS data has revealed no new adverse drug reactions since the 10-year follow-up. Therefore, treatment with GH seems a low-risk intervention in
children and adolescents with various growth disorders.
The process of developing disease-specific growth response prediction models has been ongoing in KIGS for many years. The available models are accurate, precise and have a relatively high degree of predictive power, although further predictors of the growth response remain to be identified. The KIGS prediction models can be applied prospectively to new patients, enabling their GH therapy to be better tailored and monitored to achieve optimal growth, safety and cost outcomes.
The future of KIGS within the era of evidence-based medicine will continue to depend upon the quality of the data reported. Therefore, the commitment of participating physicians will continue to be a decisive element. The ongoing recognition of the importance of valid safety and efficacy information in the practice of paediatric endocrinology is exemplified by this valuable international collaboration of clinicians and the pharmaceutical community.
Sprache
Verlagsort
Zielgruppe
Illustrationen
Gewicht
ISBN-13
978-3-8055-8256-8 (9783805582568)
Schweitzer Klassifikation
KIGS: Structure and Organization; Assessment of Growth and Puberty; Diagnosis of Children with Short Stature: Insights from KIGS; Data Analyses within KIGS; The KIGS Aetiology Classification System; GH Deficiency: GH Tests and GH Measurements; GH Testing in KIGS; GH Deficiency and Modalities of Birth; Modalities and Characteristics at Birth: Commentaries Based on KIGS Data; The Role of Insulin-Like Growth Factors in GH Deficiency; Insulin-Like Growth Factor 1 Levels in Patients within the KIGS Database; Neuroimaging in GH Deficiency; Characteristics of Idiopathic GH Deficiency at the Start of GH Therapy and the Response to GH; Idiopathic GH Deficiency in KIGS: Selected Aspects; GH Deficiency: Puberty and Final Height; GH Treatment to Final Height in Idiopathic GH Deficiency: The KIGS Experience; The Transition from Childhood to Adulthood: Managing Those with GH Deficiency; Effect of Prior Pediatric GH Replacement on Serum Lipids and Quality of Life in Young Adults with Reconfirmed Severe GH Deficiency: The Combined KIGS and KIMS Experiences; Who Stops GH in KIGS - And Why?; Congenital GH Deficiency; GH Deficiency of Known Origin within KIGS (Code No. 2.1.1-2.1.6); GH Treatment of Children with Previous Craniopharyngioma: The KIGS Experience; GH Treatment in Rare Disorders: The KIGS Experience; Childhood Brain Tumours and GH Treatment; KIGS Patients with Acquired GH Deficiency (Code No. 2.2 ff.); GH Treatment of Children with Previous Leukaemia and Lymphoma: The KIGS Experience; GH, Langerhans Cell Histiocytosis and Neurofibromatosis; GH Treatment in Neurofibrosis Type 1 Involving Central Nervous System Tumours and Pituitary Langerhans Cell Histiocytosis within KIGS; Growth and GH Treatment in Patients with Juvenile Idiopathic Arthritis; The KIGS Experience with GH Treatment of Juvenile Rheumatoid Arthritis; Cystic Fibrosis - GH Treatment; The KIGS Experience with GH Treatment of Cystic Fibrosis; Idiopathic Short Stature: Definition, Spontaneous Growth and Response to Treatment; Short- and Long-Term Response to GH in Idiopathic Short Stature: KIGS Analysis of Factors Predicting Growth; Turner Syndrome - GH Treatment; Turner Syndrome within KIGS Including an Analysis of 1146 Patients Grown to Near Adult Height; Noonan Syndrome; Short Stature in Noonan Syndrome: Results of GH Treatment in KIGS; GH Treatment in Skeletal Dysplasias: The KIGS Experience; Prader-Willi Syndrome and GH Treatment; Effects of GH Treatment in Children Presenting with Prader-Willi Syndrome: The KIGS Experience; Growth and GH Treatment in Children Born Small for Gestational Age and with Silver-Russell Syndrome; KIGS 20 Years: Children Born Small for Gestational Age; GH Treatment in Short Children with Chronic Kidney Disease; Predicting Growth in Response to GH Treatment - The KIGS Approach; Adverse Events Reported in KIGS; Progress and Challenges in Understanding the Psychology of Growth Delay; GH and Brain Function; Review of Methods for Body Composition Assessment in Children; Metabolic Effects of GH; The Growth Plate; Pharmacogenetics of GH Therapy.
